Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence - PubMed (original) (raw)
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence
Lesley A Anderson et al. Cancer Res. 2006.
Abstract
Observational studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of esophageal adenocarcinoma, but it is not known at what stage they may act in the esophageal inflammation-metaplasia-adenocarcinoma sequence. In an all-Ireland case-control study, we investigated the relationship between the use of NSAIDs and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Patients with esophageal adenocarcinoma, long-segment Barrett's esophagus and population controls were recruited from throughout Ireland. Esophagitis patients were recruited from Northern Ireland only. Data were collected on known and potential risk factors for esophageal adenocarcinoma and on the use of NSAIDs, including aspirin, at least 1 year before interview. Associations between use of NSAIDs and the stages of the esophageal inflammation-metaplasia-adenocarcinoma sequence were estimated by multiple logistic regression. In total, 230 reflux esophagitis, 224 Barrett's esophagus, and 227 esophageal adenocarcinoma and 260 population controls were recruited. Use of aspirin and NSAIDs was associated with a reduced risk of Barrett's esophagus [odds ratio [OR; 95% confidence interval (95% CI)], 0.53 (0.31-0.90) and 0.40 (0.19-0.81), respectively] and esophageal adenocarcinoma [OR (95% CI), 0.57 (0.36-0.93) and 0.58 (0.31-1.08), respectively]. Barrett's esophagus and esophageal adenocarcinoma patients were less likely than controls to have used NSAIDs. Selection or recall bias may explain these results and the results of previous observational studies indicating a protective effect of NSAIDs against esophageal adenocarcinoma. If NSAIDs have a true protective effect on the esophageal inflammation-metaplasia-adenocarcinoma sequence, they may act early in the sequence.
Similar articles
- Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P, Hendrickse MT, Isaacs PE. Tsibouris P, et al. Aliment Pharmacol Ther. 2004 Sep 15;20(6):645-55. doi: 10.1111/j.1365-2036.2004.02150.x. Aliment Pharmacol Ther. 2004. PMID: 15352913 - The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
Anderson LA, Cantwell MM, Watson RG, Johnston BT, Murphy SJ, Ferguson HR, McGuigan J, Comber H, Reynolds JV, Murray LJ. Anderson LA, et al. Gastroenterology. 2009 Mar;136(3):799-805. doi: 10.1053/j.gastro.2008.12.005. Epub 2008 Dec 3. Gastroenterology. 2009. PMID: 19162028 - No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, McGuigan J, Reynolds JV, Hardie LJ. Ferguson HR, et al. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):736-9. doi: 10.1158/1055-9965.EPI-07-2832. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18349297 - Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA, Anderson M. Jankowski JA, et al. Aliment Pharmacol Ther. 2004 Oct;20 Suppl 5:71-80; discussion 95-6. doi: 10.1111/j.1365-2036.2004.02143.x. Aliment Pharmacol Ther. 2004. PMID: 15456468 Review. - Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
Wang F, Lv ZS, Fu YK. Wang F, et al. Dis Esophagus. 2011 Jul;24(5):318-24. doi: 10.1111/j.1442-2050.2010.01153.x. Epub 2010 Dec 17. Dis Esophagus. 2011. PMID: 21166737 Review.
Cited by
- Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis.
Reid BJ, Li X, Galipeau PC, Vaughan TL. Reid BJ, et al. Nat Rev Cancer. 2010 Feb;10(2):87-101. doi: 10.1038/nrc2773. Nat Rev Cancer. 2010. PMID: 20094044 Free PMC article. Review. - Association between circulating levels of sex steroid hormones and esophageal adenocarcinoma in the FINBAR Study.
Petrick JL, Falk RT, Hyland PL, Caron P, Pfeiffer RM, Wood SN, Dawsey SM, Abnet CC, Taylor PR, Guillemette C, Murray LJ, Anderson LA, Cook MB. Petrick JL, et al. PLoS One. 2018 Jan 17;13(1):e0190325. doi: 10.1371/journal.pone.0190325. eCollection 2018. PLoS One. 2018. PMID: 29342161 Free PMC article. - Chemoprevention of esophageal adenocarcinoma.
Abrams JA. Abrams JA. Therap Adv Gastroenterol. 2008 Jul;1(1):7-18. doi: 10.1177/1756283X08093568. Therap Adv Gastroenterol. 2008. PMID: 21180511 Free PMC article. - Dietary fat and meat intakes and risk of reflux esophagitis, Barrett's esophagus and esophageal adenocarcinoma.
O'Doherty MG, Cantwell MM, Murray LJ, Anderson LA, Abnet CC; FINBAR Study Group. O'Doherty MG, et al. Int J Cancer. 2011 Sep 15;129(6):1493-502. doi: 10.1002/ijc.26108. Int J Cancer. 2011. PMID: 21455992 Free PMC article. - Current status and future perspectives on the etiology of esophageal adenocarcinoma.
Thrift AP, Pandeya N, Whiteman DC. Thrift AP, et al. Front Oncol. 2012 Feb 13;2:11. doi: 10.3389/fonc.2012.00011. eCollection 2012. Front Oncol. 2012. PMID: 22655259 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical